Published January 30, 2021 | Version v1
Journal article Open

EVALUATION OF HORMONAL AND METABOLIC PARAMETERS, ALONG WITH CARDIOVASCULAR RISK FACTORS IN WOMEN WITH NON-ALCOHOLIC FATTY LIVER DISEASE COMBINED WITH SUBCLINICAL HYPOTHYROIDISM DEPENDING ON AGE

Creators

  • 1. Government Institution "L. T. Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine"
  • 2. National Aerospace University "Kharkiv Aviation Institute"

Description

Patients with NAFLD (non-alcoholic fatty liver disease) and subclinical hypothyroidism are at risk of cardiovascular complications that cause cardiometabolic changes, thus enabling to broaden our understanding of the cardiovascular events risk in a comorbid patient. The aim: The study of hormonal and metabolic indicators and cardiovascular risk factors in women from NAFLD combined with SH (subclinical hypothyroidism) depending on the age. Materials and methods: 128 patients with NAFLD were studied, which were divided into 2 groups: І group – patients with NAFLD and level of thyroid-stimulating hormone (TSH) – 4 to 10 mIU/mL (n=45), ІІ group - patients with NAFLD and level of TSH >10 mIU/mL (n=49). The control group consisted of 34 NAFLD patients without SH. Depending on the level of TSH and age, degree of cardiovascular risk, indicators of carbohydrate and lipid metabolism, as well as the indicators that reflect ED were evaluated. Results: Comparison of metabolic parameters in two groups showed a significant difference (p<0.01 between indicators depending on the TSH level, where patients were below 50 years of age: HbA1c, LDL cholesterol, HDL cholesterol, gamma-glutamyltranspeptidase (GGTP). The levels of CDEC (circulating desquamated endothelial cells), VEGF (vascular endothelial growth factor), CRP (C-reactive protein) and TNF-α (tumor necrosis factor-α) were dependent not only on TSH, but also on age. Significant differences (p=0.001) were obtained in patients aged ≤ 50 years: CDEC; VEGF, CRP; TNF-α. Conclusions: Patients from NAFLD combined with SH have hormonal-metabolic disorders, and their degree depends on the TSH level. Early cardiometabolic changes in women are formed already at the age under 50 years, which indicates the formation of early atherosclerotic vascular changes

Files

EVALUATION OF HORMONAL AND METABOLIC PARAMETERS, ALONG WITH CARDIOVASCULAR RISK FACTORS IN WOMEN WITH NON-ALCOHOLIC FATTY LIVER DISEASE COMBINED WITH SUBCLINICAL HYPOTHYROIDISM DEPENDING ON AGE.pdf

Files (373.2 kB)

Additional details

References

  • Anokhina, H. A., Kharchenko, V. V., Dynnyk, O. B. (2018). Rol zapalennia ta metabolichnykh porushen u prohresuvanni khronichnykh zakhvoriuvan pechinky: profilaktyka ta likuvannia. Zdorovia Ukrainy, 15-16, 60–62.
  • Athyros, V. G., Alexandrides, T. K., Bilianou, H., Cholongitas, E., Doumas, M., Ganotakis, E. S. et. al. (2017). The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism: clinical and experimental, 71, 17–32. doi: http://doi.org/10.1016/j.metabol.2017.02.014
  • Mehran, L., Amouzegar, A., Azizi, F. (2019). Thyroid disease and the metabolic syndrome. Current Opinion in Endocrinology & Diabetes and Obesity, 26 (5), 256–265. doi: http://doi.org/10.1097/med.0000000000000500
  • Anokhina, H. A. (2019). Henderni osoblyvosti perebihu y terapii nealkoholnoi zhyrovoi khvoroby pechinky. Zdorovia Ukrainy. Tematychnyi nomer «Hastroenterolohiia. Hepatolohiia. Koloproktolohiia», 2, 21.
  • Danese, M. D., Gleeson, M., Kutikova, L., Griffiths, R. I., Khunti, K., Seshasai, S. R. K., Ray, K. K. (2017). Management of lipid-lowering therapy in patients with cardiovascular events in the UK: a retrospective cohort study. BMJ Open, 7 (5), e013851. doi: http://doi.org/10.1136/bmjopen-2016-013851
  • Liu, L., Yu, Y., Zhao, M., Zheng, D., Zhang, X., Guan, Q. et. al. (2017). Benefits of Levothyroxine Replacement Therapy on Nonalcoholic Fatty Liver Disease in Subclinical Hypothyroidism Patients. International Journal of Endocrinology, 2017, 1–10. doi: http://doi.org/10.1155/2017/5753039
  • Selmer, C., Olesen, J. B., Hansen, M. L., von Kappelgaard, L. M., Madsen, J. C., Hansen, P. R. et. al. (2014). Subclinical and Overt Thyroid Dysfunction and Risk of All-Cause Mortality and Cardiovascular Events: A Large Population Study. The Journal of Clinical Endocrinology & Metabolism, 99 (7), 2372–2382. doi: http://doi.org/10.1210/jc.2013-4184
  • Ludwig, U., Holzner, D., Denzer, C., Greinert, A., Haenle, M. M. et. al. (2015). Subclinical and clinical hypothyroidism and non-alcoholic fatty liver disease: a cross-sectional study of a random population sample aged 18 to 65 years. BMC Endocrine Disorders, 15 (1). doi: http://doi.org/10.1186/s12902-015-0030-5
  • Aksoy, N., Yeler, M. T., Ayan, N. N., Ozkeskin, A., Ozkan, Z., Serin, N. O. (2015). Association between thyroid hormone levels and insulin resistance and body mass index. Pakistan journal of medical sciences, 31 (6), 1417–1420. doi: http://doi.org/10.12669/pjms.316.7560
  • Chatrath, H., Vuppalanchi, R., Chalasani, N. (2012). Dyslipidemia in Patients with Nonalcoholic Fatty Liver Disease. Seminars in Liver Disease, 32 (1), 22–29. doi: http://doi.org/10.1055/s-0032-1306423
  • Ross, D. S., Burch, H. B., Cooper, D. S., Greenlee, M. C., Laurberg, P., Maia, A. L. et. al. (2016). 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid, 26 (10), 1343–1421. doi: http://doi.org/10.1089/thy.2016.0229
  • Cahill, P. A., Redmond, E. M. (2016). Vascular endothelium – Gatekeeper of vessel health. Atherosclerosis, 248, 97–109. doi: http://doi.org/10.1016/j.atherosclerosis.2016.03.007
  • Newsome, J. S. (2016). Evaluation of Statin Treatment for Nonalcoholic Fatty Liver Disease. Journal of Pharmacy Technology, 32 (4), 169–173. doi: http://doi.org/10.1177/8755122516640800
  • Yahmur, V. B. (2013). Nealkoholna zhyrova khvoroba pechinky: suchasnyi pohliad na patohenez, diahnostyku ta likuvannia. Hastroenterolohiia, 3 (49), 138–147.
  • Iaresko, M., Kolesnikova, E. (2016). The role of polymorphism-634 G/C (rs 2010963) of VEGF gene in the development of hypertension and obesity in premenopausal women. Georg. Med News, 256-257, 33–37.
  • Zhao, T., Chen, B., Zhou, Y., Wang, X., Zhang, Y., Wang, H., Shan, Z. (2017). Effect of levothyroxine on the progression of carotid intima-media thickness in subclinical hypothyroidism patients: a meta-analysis. BMJ Open, 7 (10), e016053. doi: http://doi.org/10.1136/bmjopen-2017-016053
  • Svare, A., Nilsen, T. I. L., Bjøro, T., Åsvold, B. O., Langhammer, A. (2011). Serum TSH related to measures of body mass: longitudinal data from the HUNT Study, Norway. Clinical Endocrinology, 74 (6), 769–775. doi: http://doi.org/10.1111/j.1365-2265.2011.04009.x
  • Bonci, E., Chiesa, C., Versacci, P., Anania, C., Silvestri, L., Pacifico, L. (2015). Association of Nonalcoholic Fatty Liver Disease with Subclinical Cardiovascular Changes: A Systematic Review and Meta-Analysis. BioMed Research International, 2015, 1–11. doi: http://doi.org/10.1155/2015/213737
  • Sinn, D. H., Cho, S. J., Gu, S., Seong, D., Kang, D., Kim, H. et. al. (2016). Persistent Nonalcoholic Fatty Liver Disease Increases Risk for Carotid Atherosclerosis. Gastroenterology, 151 (3), 481–488.e1. doi: http://doi.org/10.1053/j.gastro.2016.06.001
  • Bano, A., Chaker, L., Plompen, E. P. C., Hofman, A., Dehghan, A., Franco, O. H. et. al. (2016). Thyroid Function and the Risk of Nonalcoholic Fatty Liver Disease: The Rotterdam Study. The Journal of Clinical Endocrinology & Metabolism, 101 (8), 3204–3211. doi: http://doi.org/10.1210/jc.2016-1300
  • Sharma, R., Sharma, T. K., Kaushik, G. G., Sharma, S., Vardey, S. K., Sinha, M. (2011). Subclinical hypothyroidism and its association with cardiovascular risk factors. Clinical laboratory, 57 (9-10), 719–724.
  • Sarzosa Terán, V., Astudillo Calle, M. A. (2012). Relationship of thyroid-stimulating hormone levels to development of dyslipidemia and determination of an ideal cut-off point to start replacement therapy. Endocrinologia y nutricion, 59 (10), 575–582. doi: http://doi.org/10.1016/j.endonu.2012.07.006
  • Boekholdt, S. M., Titan, S. M., Wiersinga, W. M., Chatterjee, K., Basart, D. C. G., Luben, R. et. al. (2010). Initial thyroid status and cardiovascular risk factors: The EPIC-Norfolk prospective population study. Clinical Endocrinology, 72 (3), 404–410. doi: http://doi.org/10.1111/j.1365-2265.2009.03640.x
  • Erman, H., Gelisgen, R., Cengiz, M., Tabak, O., Erdenen, F., Uzun, H. (2016). The association of vascular endothelial growth factor, metalloproteinases and their tissue inhibitors with cardiovascular risk factors in the metabolic syndrome. European review for medical and pharmacological sciences, 20 (6), 1015–1022.
  • Cho, K. I., Lee, J. H. (2014). The impact of thyroid autoimmunity on arterial stiffness in postmenopausal patients with fibromyalgia. International Journal of Rheumatic Diseases, 20 (12), 1978–1986. doi: http://doi.org/10.1111/1756-185x.12257
  • Sun, J., Yao, L., Fang, Y., Yang, R., Chen, Y., Yang, K., Tian, L. (2017). Relationship between Subclinical Thyroid Dysfunction and the Risk of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Prospective Cohort Studies. International Journal of Endocrinology, 2017, 1–15. doi: http://doi.org/10.1155/2017/8130796